We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » JAK Inhibitors Take a Hit as FDA Requires Serious Box Label Warnings
JAK Inhibitors Take a Hit as FDA Requires Serious Box Label Warnings
Janus kinase (JAK) inhibitor anti-inflammatories made by Pfizer, AbbVie and Eli Lilly for inflammatory diseases, such as rheumatoid arthritis and ulcerative colitis, have all received the strictest warnings added to their labels by the FDA, which cited risk of serious health issues and the possibility of death in patients age 50 and over.